Table 1. Characteristic of included studies in this meta-analysis.

Author	Year	Country	No.	Participant	Treatment	Control	Duration
Hayoz (34)	2012	Switzerland	125	Aged 50-75 years; SBP ≥140 mmHg, DBP <110 mmHg, and PP ≥50 mmHg	Valsartan	Amlodipine	38 weeks
Ichihara (6)	2006	Japan	100	Untreated hypertensive patients; SBP ≥140 mmHg and/or DBP <110 mmHg; 24-h ambulatory SBP of ≥135 mmHg and/or 24-h ambulatory DBP of ≥80 mmHg	Valsartan	Amlodipine	12 months
Kim (33)	2014	Korea	201	Age ≥18 years; SBP >140 mmHg and/or DBP >90 mmHg	Losartan	Carvedilol	24 weeks
Klingbeil (32)	2002	Germany	60	Age: 20-70 years; SBP: 160-220 mmHg; DBP: 95-115 mmHg	Valsartan	HCTZ	6 weeks
Kosch (31)	2008	Germany	68	DBP: 90-110 mmHg	Valsartan	Metoprolol	12 weeks
Morimoto (30)	2006	Japan	43	Untreated essential hypertension	Telmisartan	Amlodipine	24 weeks
Munakata (29)	2004	Japan	41	Age 20-70 years; SBP >140 mmHg; DBP >90 mmHg	Valsartan	Nifedipine	12 weeks
Pozzobon (28)	2014	Brazil	47	Systemic arterial hypertension and type 2 diabetes mellitus; age 40-70	Losartan	Amlodipin	6 weeks
Schneider (27)	2008	Germany	168	Age of 25-65 years; SBP: 150-200 mmHg; DBP: 95-115 mmHg	Irbesartan	Atenolol	18 months
Takami (8)	2003	Japan	40	Male hypertensive patients aged 65 years or older	Valsartan	Nifedipine	24 weeks